PORTFOLIO of companies
PORTFOLIO of companies
Advanced Bionics® is dedicated to the development of neurostimulation products: implantable devices that generate sophisticated electrical pulses directed to nerves and muscles for the treatment of disabling conditions. Advanced Bionics technologies include treatments for deafness and chronic pain. The company is also developing other sophisticated neurostimulation devices to address additional challenges in many fields including blindness, tremor and spasticity, urinary incontinence, and functional restoration of paralyzed limbs.
Advanced Bionics has been acquired by Boston Scientific Corporation.
Agile RF uses a novel material technology to design and fabricate tunable integrated components that have a wide range of applications in wireless communications. The key feature of Agile’s components and circuits is tunability; making their products much more than simply integrated passive circuits. Agile’s expertise in materials science and RF circuit design has enabled them to exploit the properties of newly developed thin film materials in innovative RF designs.
Agile has exclusively licensed certain of its key technologies to TriQuint.
ALSIUS (Latin translation for “Cool”) is the worldwide leader in advanced patient temperature management therapies. Alsius Intravascular Temperature Management™ gives health care providers the power and control they need to rapidly, safely, and effectively manage the core body temperature of critically ill or surgical patients.
Alsius has been acquired by a wholly-owned subsidiary of ZOLL Medical Corporation.
Calimmune is committed to accelerating the promise of gene therapy to liberate patients from chronic and currently incurable diseases. To achieve this goal, Calimmune has built a suite of technologies to advance the delivery, manufacturing, and overall efficiency of these life-changing medicines. Calimmune’s lead development programs are novel ex vivo gene therapies for HIV and other hematologic diseases.
Calimmune has been acquired by CSL Behring.
Centaur Pharmaceuticals developed a novel class of small molecule pharmaceutical compounds for the treatment of neurodegenerative and inflammatory diseases such as acute stroke, dementia, rheumatoid arthritis, myocardial ischemia and Parkinson’s disease. Renovis is a biopharmaceutical company with a primary focus on the discovery, development and commercialization of drugs to treat neurological diseases and disorders.
Renovis acquired Centaur Pharmaceuticals, Inc. in December 2002.
ClarVista has developed the Harmoni modular intra-ocular lens system. The two piece Harmoni IOL system enables vision optimization through better initial positioning of the lens, and the safe and easy exchange of the lens optic when required. Initial studies also indicate that the risk of development of secondary cataracts is significantly reduced by the Harmoni system.
ClarVista has been acquired by Alcon.
The combined entity of Clean Diesel Technologies (CDTI) and Catalytic Solutions, Inc. (CSI) is a vertically integrated global manufacturer and distributor of emissions control systems and products. It is focused on the heavy duty diesel and light duty vehicle markets. CSI invented Mixed Phase Catalyst technology, a fundamentally unique and patented materials technology for the development of catalysts for emissions control and chemical processes.
CDTI and CSI merged in December 2010.
Formetrix designs, produces and sells easy to print, proprietary, high performance steel alloy powder for 3D printed components and metal injection molding. Focus areas include hot and cold forming tool and dies (molding, casting and stamping) within the automotive, oil and gas and heavy machinery markets.
FzioMed is engaged in the development and commercialization of advanced, absorbable biosurgery products. FzioMed’s product platform is an innovative polymer technology called Oxiplex®. The properties of Oxiplex make it an ideal and versatile biosurgery material. A key focus for use of Oxiplex® is the prevention of post-surgical adhesions. Adhesions are abnormal fibrous bands of scar tissue that form attachments to normally independent organs and tissues. Adhesions create complications which may require further surgical intervention.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. The Company has developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea uses ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, while also exploring partnership opportunities for general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus. Genocea expects to begin clinical development of its first neoantigen cancer vaccine, GEN-009, in 2018.
GRT, Inc. has developed proprietary process chemistry that converts methane to gasoline or other hydrocarbon fuels and chemicals. The GRT process is highly flexible and can be applied to make a wide variety of high volume chemicals and liquid fuels including olefins, aromatics, and high octane gasoline blend stocks. Unlike current technologies (Fischer-Tropsch chemistry and thermal cracking), GRT’s technology does not require high temperatures or pressures to create the gas to liquids reactions, thus providing significant savings in capital costs and operating expenses.
GRT has licensed certain of its key technologies to Marathon Oil Corporation.
ImaginAb facilitates the promise of personalized medicine through creation of companion diagnostics for patient stratification and targeted molecular therapy. ImaginAb’s technology enables antibodies to be re-engineered into smaller proteins (fragments) with rapid kinetics suitable for diagnostic imaging, while maintaining target biospecificity. In this way true companion in vivo diagnostics can be developed that enable target expression to be profiled in tissues in a non-invasive, whole-body manner.
Intarcia is developing innovative therapies utilizing its Medici Drug Delivery System™ that can transform the prevention and management of serious chronic diseases by optimizing the efficacy, continuous administration and tolerability of drug therapies. The Medici Drug Delivery System™ is a proprietary subcutaneous delivery system comprised of: a technology that stabilizes proteins, peptides, antibody fragments, and other highly potent small molecules at or above human body temperatures for three years or more; a matchstick-sized osmotic pump that is placed just under the skin to deliver a continuous and consistent flow of medication; and placement technology. Intarcia is currently using the Medici Drug Delivery System™ to target Type 2 Diabetes.
NanoSteel combines the compelling attributes of iron-based alloys with new chemistries and mechanisms to deliver material properties and performance characteristics outside the boundaries of existing steels. NanoSteel has created progressive generations of iron-based alloys from metallic coatings to foils to powder metals and sheet steel. Current focus areas are strong and formable sheet steels (a combination of high strength and high ductility in cold formable steel) for automotive lightweighting applications and hard metal powders for 3D printing.
OvaScience is focused on the discovery, development and commercialization of new treatments for female infertility. Utilizing patented technology, OvaScience is translating innovative research in egg precursor germline stem cells to make in vitro fertilization (IVF) safer and more effective.
OvaScience merged with Millendo Therapeutics
Sirtris Pharmaceuticals is a biopharmaceutical company discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Its drug candidates are designed to mimic the beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of an enzyme called SIRT1, a member of a recently discovered class of enzymes called sirtuins.
Sirtris has been acquired by GlaxoSmithKline.
Solaria Corp. manufactures low-concentration photovoltaic modules designed for ground-mounted tracking systems. Solaria’s proprietary manufacturing processes require only a fraction of the capital per watt of manufacturing capacity needed by standard industry processes. Based on its patented technology, Solaria’s modules provide reliable performance while matching form, fit and performance of conventional PV modules.
SteriFx, Inc. is a specialty chemical company producing non-toxic antimicrobial solutions for the food safety, industrial, consumer, healthcare, and military/homeland defense markets. The patented technology is a low pH (<1) aqueous solution that is highly effective in controlling pathogens (viruses, bacteria and fungi) with no toxicity when properly used. The Company’s products have received regulatory approvals from the USDA/FSIS, EPA and FDA for a variety of applications.
SteriFx was acquired in a private transaction.
Tilford Pinson Exploration, LLC (TPX) is an oil and gas exploration and development company focused in the Arkoma Basin of southeastern Oklahoma. TPX employs state-of-the-art technology to maximize production in the short term while creating long term value via future drilling opportunities. Pittsburg Gathering LLC designs, builds, and operates natural gas gathering systems.
Founded by aerospace pioneer Charles “Pete” Conrad, Jr., Universal Space Network, Inc. (USN) is a leader in space operations for telemetry, tracking and control (TT&C) services. Offering responsive, reliable and cost-effective solutions to the global government and commercial space community, USN provides unparalleled coverage through a seamless network of worldwide satellite tracking and communications assets. USN has been acquired by The Swedish Space Corporation.
Unity focuses on the development of therapeutics that extend the human healthspan through intervention in the biological mechanisms associated with aging, thus enabling people to be healthier as they live longer. The Company’s initial emphasis is on “senolytics”—therapeutics that selectively eliminate senescent cells that accumulate with age. Unity’s first clinical programs are expected to include inflammatory joint diseases (osteoarthritis) and ophthalmology (glaucoma and age related macular degeneration).
Urban Electric Power (UEP) is commercializing proprietary zinc anode rechargeable battery technology for applications ranging from car batteries, to power protection to grid-scale storage. UEP technology uses non-toxic, 100% recyclable materials without lead, heavy metals, or flammable electrolytes. UEP offers substantial cost benefits compared to existing battery chemistries because of the extended cycle life, high capacity at high charge/discharge rates, and low cost of starting materials.
Visterra uses its proprietary computational technology to generates unique information that guides the discovery and development of novel antibodies for the treatment and prevention of major diseases. The company’s lead product candidates are a broad spectrum human monoclonal antibody for the prevention and treatment of both seasonal and pandemic influenza, and an antibody to treat all four strains of dengue virus.
Visterra was acquired by Otsuka Pharmaceutical.
ZIOPHARM is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment.